Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm
You may also be interested in...
SciClone China CEO Mark Lotter On The Changing Commercial Landscape: An Interview With PharmAsia News (Part 2 of 2)
Considered one of the top commercial minds in China, the former AstraZeneca exec and founder of NovaMed discusses how to build a sustainable commercial model in a rapidly changing China, touching on everything from retaining talent to surviving China’s latest round of price cuts.
SciClone China CEO Mark Lotter On The Changing Commercial Landscape: An Interview With PharmAsia News (Part 1 of 2)
Considered one of the top commercial minds in China, the former AstraZeneca exec and founder of NovaMed discusses how to build a sustainable commercial model in a rapidly changing China, touching on everything from retaining talent to surviving China’s latest round of price cuts.
A Long Way Still For Corrupt Business Practices In China, India - Pharmaceutical Regulatory And Compliance Congress
SINGAPORE - Major Chinese pharma companies are eyeing acquisitions of companies in lucrative Western markets to establish a global foothold, according to industry observers